Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/Ib Study of NY-ESO-1 TCR/IL-15 NK Cells in Advanced Sarcomas
NCT06083883Phase 1Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Mar 2024
- Primary completion
- Nov 2026
- Modality
- TCR-Engineered T Cells, Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of NY-ESO-1 TCR + IL-15 NK in synovial sarcoma (SS) and myxoid round cell liposarcoma (MRCLPS), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Incidence of Adverse Events at 1 year. Started Mar 2024; status: recruiting.
02
Drugs
NY-ESO-1 TCR + IL-15 NK
03
Conditions
synovial sarcoma (SS)myxoid round cell liposarcoma (MRCLPS)
Beyond the preview
Go deeper on NCT06083883.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06083883.